Inventor
WAX MARTIN B
US18 patents
⚠️ This page may combine multiple inventors who share the name “WAX MARTIN B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PANOPTICA INC
6 patentsUS9446026B2Sep 20, 2016
Ocular formulations for drug-delivery to the posterior segment of the eye
PANOPTICA INC8 citations81
US10307404B1Jun 4, 2019
Ocular formulations for drug-delivery to the posterior segment of the eye
PANOPTICA INC2 citations70
US10183014B2Jan 22, 2019
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
PANOPTICA INC2 citations70
US10092549B2Oct 9, 2018
Ocular formulations for drug-delivery to the posterior segment of the eye
PANOPTICA INC2 citations70
US9814702B2Nov 14, 2017
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
PANOPTICA INC2 citations70
US9623011B2Apr 18, 2017
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
PANOPTICA INC2 citations70
ARROWHEAD RES CORP
3 patentsUS9476047B2Oct 25, 2016
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
ARROWHEAD RES CORP1 citations62
US9422556B2Aug 23, 2016
RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis
ARROWHEAD RES CORP0 citations50
US9139834B2Sep 22, 2015
RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis
ARROWHEAD RES CORP0 citations50
CHATTERTON JON E
3 patentsUS9173896B2Nov 3, 2015
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
CHATTERTON JON E0 citations51
US8865670B2Oct 21, 2014
RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma
CHATTERTON JON E0 citations50
US8754202B2Jun 17, 2014
RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis
CHATTERTON JON E0 citations50